Research scientists found that a ‘one-two punch’ of combining the immunosuppressive drug ruxolitinib with existing checkpoint inhibitor therapies may be a more effective way to fight some cancers, including Hodgkin lymphoma. Checkpoint inhibitor therapies can be thought of as the molecular ‘brake release’ for the immune system. These drugs eliminate the protein barriers that impede the immune system from recognizing and targeting cancer cells in the body.
